Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"NTC","sponsor":"Taro Pharmaceutical Industries","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NTC Grants License and Distribution Rights in Israel to Taro Pharmaceutical Industries","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"ITALY","productType":"Small molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III"},{"orgOrder":0,"company":"NTC","sponsor":"I-MED","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NTC and I-MED Pharma Form Strategic Partnership to Bring the Leading HA-Based Dry Eye Ointment to The United States Market","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"ITALY","productType":"Small molecule","productStatus":"Approved","date":"December 2021","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by NTC S.r.l

    Menu

    NTC S.r.l

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              NTC

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Italy
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              NTC and I-MED Pharma Form Strategic Partnership to Bring the Leading HA-Based Dry Eye Ointment to The United States Market

              Details:

              NTC and I-MED Pharma’s successful collaboration to bring I-DEFENSE® innovative ophthalmic ointment first to Canada and now to the U.S.A. is a testament to the dedication of both companies to advancing the science of dry eye.

              Lead Product(s): Sodium Hyaluronate

              Therapeutic Area: Ophthalmology Product Name: I-Defense

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: I-MED

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership December 15, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              NTC

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Italy
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              NTC Grants License and Distribution Rights in Israel to Taro Pharmaceutical Industries

              Details:

              NTC Srl has granted exclusive license and distribution rights to one of its R&D products to Taro Pharmaceutical. The product combines a quinolone antibiotic with an anti-inflammatory steroid in eye drops intended to provide an appropriate treatment for post-cataract surgery.

              Lead Product(s): Levofloxacin,Dexamethasone

              Therapeutic Area: Ophthalmology Product Name: Undisclosed

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Taro Pharmaceutical Industries

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement June 17, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY